-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Q9S7dgixmzuJZEX6QhoIuyuxNBMquJFV/XFXqulRnEQ/QoqjTlKHn1+SV+Etuh5r
 4zfHyKG58T4ty9inqD4m8w==

<SEC-DOCUMENT>0000318306-06-000020.txt : 20060907
<SEC-HEADER>0000318306-06-000020.hdr.sgml : 20060907
<ACCEPTANCE-DATETIME>20060907123507
ACCESSION NUMBER:		0000318306-06-000020
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20060901
ITEM INFORMATION:		Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
FILED AS OF DATE:		20060907
DATE AS OF CHANGE:		20060907

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ACCESS PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000318306
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				830221517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15771
		FILM NUMBER:		061078638

	BUSINESS ADDRESS:	
		STREET 1:		2600 N STEMMONS FRWY
		STREET 2:		STE 176
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75207
		BUSINESS PHONE:		2149055100

	MAIL ADDRESS:	
		STREET 1:		2600 N STEMMONS FRWY
		STREET 2:		STE 176
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHEMEX PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHEMEX CORP/WY
		DATE OF NAME CHANGE:	19831102
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>r8k-115.txt
<DESCRIPTION>FORM 8-K
<TEXT>
                            UNITED STATES
                  SECURITIES AND EXCHANGE COMMISSION
                        WASHINGTON, DC  20549


                                FORM 8-K

                             CURRENT REPORT

                PURSUANT TO SECTION 13 OR 15(d) OF THE
                    SECURITIES EXCHANGE ACT OF 1934


    Date of report (Date of earliest event reported): September 1, 2006




                       Access Pharmaceuticals, Inc.
           ------------------------------------------------------
           (Exact name of registrant as specified in its charter)


        Delaware                     0-9314                  83-0221517
- ------------------------    ------------------------    -------------------
(State of Incorporation)    (Commission File Number)    (I.R.S. Employer
                                                        Identification No.)


     2600 Stemmons Freeway, Suite 176, Dallas, Texas             75207
     -----------------------------------------------           ---------
        (Address of principal executive offices)               (Zip Code)


   Registrant's telephone number, including area code: (214) 905-5100
                                                       --------------



<PAGE>

Item 5.02 Departure of Directors or Principal Officers;
	    Election of Directors;
	    Appointment of Principal Officers
          ------------------------------------------

On September 1, 2006, the election became effective of a new board
member - Mark J. Ahn, PhD - to the Access Pharmaceuticals, Inc.
Board of Directors.

Dr. Ahn is currently President and CEO of Hanna Biosciences, Inc., a
South San Franciso, CA - based biopharmaceutical company which acquires,
Develops and commercializes innovative products to advance cancer care.
Previously to Hanna, Dr. Ahn served as Vice President, Hematology and
Corporate officer at Genentech, Inc. Prior to Genetech, Dr. Ahn held a
Series of positions of increasing responsibility at Bristol-Meyers
Squibb Company, Amgen, Inc. and FMC Corporation.

Effective September 1, 2006, Max Link, PhD resigned from the Board of
Directors.

A press release is attached as Exhibit 99.1 to this report and is
Incorporated herein by this reference, in which the Company announced
its new director Mark Ahn, PhD and the resignation of its director
Max Link, PhD.


                                  2

<PAGE>
                               SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.



                                          Access Pharmaceuticals, Inc.
                                                 (Registrant)

                                          By: /s/ Stephen B. Thompson
                                             ------------------
                                              Stephen B. Thompson
                                              Vice President and
                                              Chief Financial Officer

Dated September 7, 2006

                                  3

<PAGE>
				EXHIBIT INDEX

Exhibit
Number	Description
- -------	------------------
99.1		Press Release, dated September 5, 2006
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>r8k-116.txt
<DESCRIPTION>PRESS RELEASE DATED 09/05/06
<TEXT>
Exhibit 99.1

LOGO

	                            ACCESS NEWS

Contact: Company	                              Contact: Investor Relations
Stephen B. Thompson	                           Donald C. Weinberger
Vice President & CFO	                          Wolfe Axelrod Weinberger
                                                   Associates, LLC
(214) 905-5100	                                (212) 370-4500


               ACCESS PHARMACEUTICALS, INC. ANNOUNCES BOARD CHANGES

DALLAS, TEXAS, September 5, 2006 -- ACCESS PHARMACEUTICALS, INC. (ACCP.OB)
today announced the appointment of Mark J. Ahn, Ph.D. to the Board of Directors
of the Company. In addition, Max Link, Ph.D., a board member since 1996, has
announced his resignation.

Dr. Ahn is currently President and Chief Executive Officer of Hana Biosciences,
Inc., a South San Francisco, CA-based biopharmaceutical company which acquires,
develops, and commercializes innovative products to advance cancer care.

Prior to Hana, Dr. Ahn served as Vice President, Hematology and corporate
officer at Genentech, Inc. where he was responsible for commercial and
clinical development of the Hematology franchise which surpassed $1 billion
in revenues, achieved the #1 oncology therapeutic position in the US, and was
recognized as the #1 sales and marketing team in the biopharmaceutical
industry by Product Management Today. Prior to Genentech, Dr. Ahn held a
series of positions of increasing responsibility at Bristol-Myers Squibb
Company, Amgen, Inc., and FMC Corporation in strategy, general management,
sales & marketing, business development, and finance.

"I am excited by the opportunity to assist Access in advancing its drug
platform and, particularly, its cancer care product platform. My experience
in this area could be of great benefit in helping Access realize its goals
and aspirations," noted Dr. Ahn.

Commenting on the appointment, Rosemary Mazanet, M.D. Ph.D., Acting CEO of
Access, stated, "Mark's focus on commercializing advanced cancer care products
will be important as Access continues to develop its polymer platinate cancer
drug, ProLindac(TM). His experience in developing a broad array of
therapeutic products to market will complement our board of directors."

Speaking about the resignation of Dr. Link, Dr. Mazanet stated, "We are
grateful for Max's contributions to the board, over the last 10 years,
and we wish him well in his future endeavors."

               _____________________________________

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that
develops and commercializes propriety products for the treatment and
supportive care of cancer patients. Access' products include ProLindac(TM),
currently in Phase II clinical testing of patients with ovarian cancer and
MuGard(TM) for the treatment of patients with mucositis. The Company also has
other advanced drug delivery technologies including vitamin mediated targeted
delivery and oral drug delivery. For additional information on Access
Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking
within the meaning of Section 27a of the Securities Act of 1933, as amended,
and that involve risks and uncertainties, including statements relating to
the value of our products in the market, our ability to achieve clinical and
commercial success and our ability to successfully develop marketed products.
These statements are subject to numerous risks, including but not limited to
the risks detailed in the Company's Annual Report on For
e year ended December 31, 2005 and other reports filed by us with the
Securities and Exchange Commission.

                                 ###

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
